AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis

AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis

Source: 
Endpoints
snippet: 

As the competition around the lucrative atopic dermatitis space heats up, AbbVie, Janssen, Novartis, Pfizer, and UCB are coming together in a pre-competitive collaboration to advance nocturnal scratch as a “digital” endpoint for the skin condition.